MEI Pharma, Inc. (MEIP) Analysts See $-0.26 EPS

January 14, 2018 - By Dolores Ford

 MEI Pharma, Inc. (MEIP) Analysts See $ 0.26 EPS

Analysts expect MEI Pharma, Inc. (NASDAQ:MEIP) to report $-0.26 EPS on February, 14.They anticipate $0.58 EPS change or 181.25 % from last quarter’s $0.32 EPS. After having $-0.24 EPS previously, MEI Pharma, Inc.’s analysts see 8.33 % EPS growth. The stock decreased 1.05% or $0.03 during the last trading session, reaching $2.36. About 146,737 shares traded. MEI Pharma, Inc. (NASDAQ:MEIP) has risen 20.90% since January 14, 2017 and is uptrending. It has outperformed by 4.20% the S&P500.

MEI Pharma, Inc. (NASDAQ:MEIP) Ratings Coverage

Among 3 analysts covering MEI Pharma (NASDAQ:MEIP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. MEI Pharma had 7 analyst reports since September 4, 2015 according to SRatingsIntel. Wedbush maintained the shares of MEIP in report on Friday, September 4 with “Hold” rating. The rating was maintained by Oppenheimer on Wednesday, May 31 with “Buy”. Oppenheimer maintained MEI Pharma, Inc. (NASDAQ:MEIP) on Wednesday, June 14 with “Buy” rating. On Wednesday, August 2 the stock rating was maintained by Oppenheimer with “Buy”. The stock of MEI Pharma, Inc. (NASDAQ:MEIP) has “Buy” rating given on Monday, June 26 by Oppenheimer. The company was maintained on Wednesday, September 6 by Stifel Nicolaus.

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company has market cap of $87.20 million. The company??s clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. It currently has negative earnings. The Company’s clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer.

More notable recent MEI Pharma, Inc. (NASDAQ:MEIP) news were published by: Prnewswire.com which released: “MEI Pharma Reports First Quarter Fiscal Year 2018 Results” on November 08, 2017, also Seekingalpha.com with their article: “MEI Pharma’s (MEIP) CEO Dan Gold on Q4 2017 Results – Earnings Call Transcript” published on September 05, 2017, Prnewswire.com published: “MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for …” on September 05, 2017. More interesting news about MEI Pharma, Inc. (NASDAQ:MEIP) were released by: Prnewswire.com and their article: “Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan …” published on January 11, 2018 as well as Prnewswire.com‘s news article titled: “MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer” with publication date: April 03, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.